Mitsubishi, Sumitomo Could Shuffle Drug Executives To Other Global Units
This article was originally published in PharmAsia News
Mitsubishi Chemical Holdings and Sumitomo Chemical, each with drug-making subsidiaries, are among Japanese corporations looking to shift personnel as needed to create more flexible management structures.
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.